| Q37937877 | 2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapy |
| Q39442199 | A patient with four-year survival after nonsmall cell lung carcinoma with a solitary metachronous small bowel metastasis |
| Q36605647 | A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients |
| Q33427832 | A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer |
| Q37058368 | Angiogenesis in chronic obstructive pulmonary disease: a translational appraisal |
| Q46401930 | Apoptosis-inducing high (.)NO concentrations are not sustained either in nascent or in developed cancers |
| Q39139836 | Circulating tumor cells (CTCs) in lung cancer: current status and future perspectives |
| Q33779741 | Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis |
| Q33422985 | Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysis |
| Q35535417 | Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancer |
| Q55209413 | Comprehensive identification of microRNA arm selection preference in lung cancer: miR-324-5p and -3p serve oncogenic functions in lung cancer. |
| Q53297277 | Diagnostic Concordance of Histologic Lung Cancer Type Between Bronchial Biopsy and Cytology Specimens Taken During the Same Bronchoscopic Procedure |
| Q100762024 | Downregulation of microRNA-324-3p inhibits lung cancer by blocking the NCAM1-MAPK axis through ALX4 |
| Q37532320 | Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population |
| Q37645201 | Emerging treatment options in the management of non-small cell lung cancer. |
| Q48905841 | Erlotinib and brain metastases |
| Q37625444 | First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. |
| Q35864613 | Hepatic arterial therapy with drug-eluting beads in the management of metastatic bronchogenic carcinoma to the liver: a multi-institutional registry |
| Q33575266 | High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology |
| Q36051715 | Human leukocyte antigen (HLA)-G gene polymorphism in patients with non-small cell lung cancer |
| Q64098598 | Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell-Bearing Mice |
| Q39331689 | Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer. |
| Q33554085 | Lung cancer: current diagnosis and treatment |
| Q64883385 | Measurement of quality of life in second-line patients with advanced NSCLC without targetable mutations: a review. |
| Q60196643 | Modelos experimentais em oncologia: O contributo da cultura de células para o conhecimento da biologia do cancro |
| Q34560236 | Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib |
| Q30702531 | Nodal Upstaging Is More Common with Thoracotomy than with VATS During Lobectomy for Early-Stage Lung Cancer: An Analysis from the National Cancer Data Base |
| Q34075035 | Paraneoplastic syndrome mimicking adult-onset Still's disease caused by advanced lung cancer: a case report |
| Q39145896 | Pharmacoeconomic benefit of cisplatin and etoposide chemoregimen for metastatic non small cell lung cancer: An Indian study |
| Q34200743 | Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer |
| Q35584072 | Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer |
| Q34333155 | Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer |
| Q88221648 | Prognostic and predictive value of plasma D-dimer in advanced non-small cell lung cancer patients undergoing first-line chemotherapy |
| Q47137029 | Reasons for lack of referral to medical oncology for systemic therapy in stage IV non-small-cell lung cancer: comparison of 2003-2006 with 2010-2011. |
| Q30502590 | Reinforcement learning strategies for clinical trials in nonsmall cell lung cancer |
| Q41608748 | Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients. |
| Q36470768 | Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. |
| Q42153889 | Surgical Management of Non-small Cell Lung Cancer with Solitary Hematogenous Metastases |
| Q89585571 | Surgical outcomes of stage IV non-small cell lung cancer: a single-center experience |
| Q34548803 | The disparity of health facilities in an urban area discourages proposed treatment application in inoperable lung cancer patients |
| Q33599167 | The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics |
| Q38197618 | Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review). |
| Q36412597 | Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q46114940 | Treatment of the postoperative recurrence of lung cancer in octogenarians |
| Q37333926 | Treatment outcomes in elderly with advanced-stage non-small cell lung cancer |
| Q40884333 | Tumor lysis without syndrome in adenocarcinoma of the lung: Case report |
| Q37670699 | UFT and S-1 for treatment of primary lung cancer |
| Q49263988 | Upregulation of miR-146a increases cisplatin sensitivity of the non-small cell lung cancer A549 cell line by targeting JNK-2. |
| Q34637882 | Using pet-ct to reduce futile thoracotomy rates in non-small-cell lung cancer: a population-based review |
| Q37117859 | Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status? |
| Q34195513 | miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222 |